Prosecution Insights
Last updated: April 19, 2026

Examiner: VAN BUREN, LAUREN K

Tech Center 1600 • Art Units: 1632 1638 1651

This examiner grants 39% of resolved cases

Performance Statistics

38.8%
Allow Rate
-21.2% vs TC avg
463
Total Applications
+57.3%
Interview Lift
1638
Avg Prosecution Days
Based on 407 resolved cases, 2023–2026

Rejection Statute Breakdown

2.7%
§101 Eligibility
11.0%
§102 Novelty
47.5%
§103 Obviousness
23.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18029354 METHOD FOR CRYOPRESERVING A PLURALITY OF CELL CLUSTERS OF BIOLOGICAL CELLS Non-Final OA Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V.
17783265 MICRONEEDLE DELIVERY DEVICE WITH DETACHABLE HYBRID MICRONEEDLE DEPOTS FOR LOCALIZED DELIVERY OF CELLS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18015672 RAPIDLY DISSOLVING CELL CULTURE MEDIA POWDER AND METHODS OF MAKING THE SAME Final Rejection CORNING INCORPORATED
18018389 CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME Non-Final OA AMGEN INC.
16422086 PATCH GRAFT COMPOSITIONS FOR CELL ENGRAFTMENT Final Rejection The University of North Carolina at Chapel Hill
17025999 KETONE BODY SENSING DEVICE AND METHOD Final Rejection MEDTRONIC MINIMED, INC.
18558065 STRING-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID STRING-LIKE AGGREGATES Non-Final OA RIKEN
18560000 Methods and Compositions for Extending Organ and Tissue Preservation Non-Final OA The General Hospital Corporation
19028696 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS Non-Final OA Imvela Corp.
18790185 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS Final Rejection Imvela Corp.
17874136 METHODS AND APPARATUSES FOR PREPARING SPHERICAL DROPLETS Final Rejection Duke University
18608371 PLACENTAL TISSUE PARTICULATE COMPOSITIONS AND METHODS OF USE Non-Final OA Musculoskeletal Transplant Foundation
17778333 PLACENTAL TISSUE PARTICULATE COMPOSITIONS AND METHODS OF USE Non-Final OA Musculoskeletal Transplant Foundation
18016978 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DIABETES Final Rejection OSAKA UNIVERSITY
18038088 DENSITY-ADJUSTED LIQUIDS AND METHODS USING SAME Non-Final OA STEMCELL TECHNOLOGIES CANADA INC.
18584293 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS Non-Final OA OSIRIS THERAPEUTICS, INC.
17401758 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS Non-Final OA OSIRIS THERAPEUTICS, INC.
17926106 IMMUNE CELLS WITH ENHANCED FUNCTION Non-Final OA The Council of the Queensland Institute of Medical Research
18285766 CELL CULTURE COMPOSITION COMPRISING CHLORELLA EXTRACT Non-Final OA SEA WITH, INC
17291536 PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS Non-Final OA Juno Therapeutics, Inc.
18471936 METHODS AND COMPOSITIONS FOR POTENTIATING STEM CELL THERAPIES Non-Final OA Ojai Energetics PBC
17088860 ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES Non-Final OA LifeNet Health
18044955 AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS Non-Final OA BioNTech SE
18270924 CELLULAR MICROCOMPARTMENTS COMPRISING CELLS OF WHICH THE GENOMIC INTEGRITY IS MAINTAINED AFTER AMPLIFICATION AND PREPARATION METHOD Non-Final OA TREEFROG THERAPEUTICS
18060626 HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER Non-Final OA BIOGAIA AB
18024839 BIOMIMETIC WOUND HEALING DEVICES AND RELATED METHODS OF TREATING DIABETIC WOUNDS Non-Final OA Protein Genomics Inc.
18024012 ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF Non-Final OA Nkarta, Inc.
18012904 CRYOPRESERVATION METHOD FOR ORGAN-ON-A-CHIP Non-Final OA MEPSGEN CO., LTD.
16634820 COMPOSITION FOR CRYOPRESERVATION, METHOD FOR PRODUCING CRYOPRESERVED MATERIAL, CELL PREPARATION, METHOD FOR PRODUCING CELL PREPARATION, AND KIT FOR CRYOPRESERVATION Final Rejection TWO CELLS Co., Ltd.
18081136 Products Derived from Amniotic Fluid and Methods of Use Non-Final OA StimLabs LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month